



Express Mail No. EV452775245US

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 9471-011-999 (CAM: 209025-999010)	APPLICATION NO. 10/506,406
	APPLICANT Swiercz et al.	
	FILING DATE March 14, 2005	GROUP 1653 1654

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JK	A01 5,639,726	01/17/1997	Lawrence et al.			
JK	A02 6,303,338 B1	10/16/2001	Ni et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	YES	NO
JK	B01 WO 97/39028	10/23/1997	PCT					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

JK	C01	International Search Report dated 1/14/2004 of corresponding PCT Application No. PCT/US03/06679.
	C02	Achbarou et al., Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. <i>Cancer Res.</i> 1994 May 1;54(9):2372-7.
	C03	Chorostowska-Wynimko et al., A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis. <i>Mol Cancer Ther.</i> 2003 Jan;2(1):19-28.
	C04	Conese et al., The urokinase/urokinase-receptor system and cancer invasion. <i>Baillieres Clin Haematol.</i> 1995 Jun;8(2):365-89.
	C05	Danø et al., Plasminogen activators, tissue degradation, and cancer. <i>Adv Cancer Res.</i> 1985;44:139-266.
	C06	Declerck et al., Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. <i>Blood.</i> 1988 Jan;71(1):220-5.
	C07	Declerck et al., Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). <i>J Biol Chem.</i> 1988 Oct 25;263(30):15454-61.
	C08	Ellis et al., Plasminogen activation by receptor-bound urokinase. <i>Semin Thromb Hemost.</i> 1991 Jul;17(3):194-200.
	C09	Festuccia et al., Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma. <i>Oncol Res.</i> 1995;7(3-4):131-8.
	C10	Hajjar et al., Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase. <i>J Biol Chem.</i> 1990 Feb 15;265(5):2908-16.
	C11	Hekman et al., Bovine plasminogen activator inhibitor 1: specificity determinations and comparison of the active, latent, and guanidine-activated forms. <i>Biochemistry.</i> 1988 Apr 19;27(8):2911-8.
	C12	Hekman et al., Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. <i>J Biol Chem.</i> 1985 Sep 25;260(21):11581-7.
	C13	Hoylaerts et al., Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. <i>J Biol Chem.</i> 1982 Mar 25;257(6):2912-9.
	C14	Hsueh et al., Molecular mechanisms in the hormonal regulation of plasminogen activator activity in ovarian granulosa cells and cumulus-oocyte complexes. <i>Prog Clin Biol Res.</i> 1988;267:227-57.
	C15	Jankun et al., Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. <i>J Cell Biochem.</i> 1993 Oct;53(2):135-44.
	C16	Jankun et al., Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. <i>Cancer Res.</i> 1997 Feb 15;57(4):559-63. Erratum in: <i>Cancer Res</i> 1998 Jan 1;58(1):179.
	C17	Jankun et al., Malignant transformation of human fibroblasts correlates with increased activity of receptor-bound plasminogen activator. <i>Cancer Res.</i> 1991 Feb 15;51(4):1221-6.
	C18	Kwaan et al., Components of the plasminogen-plasmin system in human tumor cell lines. <i>Semin Thromb Hemost.</i> 1991 Jul;17(3):175-82.
	C19	Lawrence et al., Engineering plasminogen activator inhibitor 1 mutants with increased functional stability.

		Biochemistry. 1994 Mar 29;33(12):3643-8.
	C20	Lawrence et al., Plasminogen activator inhibitors in Molecular Basis of Thrombosis and Hemostasis. Marcel Dekker, Inc., High et al., eds. 1995;25:517-43.
	C21	Lawrence et al., Purification of active human plasminogen activator inhibitor I from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells. Eur J Biochem. 1989 Dec 22;186(3):523-33.
	C22	Levin et al., Conversion of the active to latent plasminogen activator inhibitor from human endothelial cells. Blood. 1987 Oct;70(4):1090-8.
	C23	Mayer, Biochemical and biological aspects of the plasminogen activation system. Clin Biochem. 1990 Jun;23(3):197-211.
	C24	Mayer, The pharmacokinetics of plasminogen activator inhibitor-I in the rabbit. Blood. 1990 Oct 15;76(8):1514-20.
	C25	Mimuro et al., Binding of type I plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells. J Biol Chem. 1989 Mar 25;264(9):5058-63.
	C26	Mimuro et al., Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type I plasminogen activator inhibitor. Blood. 1987 Sep;70(3):721-8.
	C27	Moscatelli et al., Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis. Biochim Biophys Acta. 1988 Aug 3;948(1):67-85.
	C28	Ossowski, In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J Cell Biol. 1988 Dec;107(6 Pt 1):2437-45.
	C29	Pepper et al., Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells. J Cell Biol. 1987 Dec;105(6 Pt 1):2535-41.
	C30	Pepper et al., Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol. 1993 Aug;122(3):673-84.
	C31	Plow et al., Cellular regulation of fibrinolysis. Thromb Haemost. 1991 Jul 12;66(1):32-6.
	C32	Pöllänen et al., Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res. 1991;57:273-328.
	C33	Rånby et al., A sensitive assay for tissue plasminogen activator. Thromb Res. 1982 Sep 15;27(6):743-9.
	C34	Saksela et al., Cell-associated plasminogen activation: regulation and physiological functions. Annu Rev Cell Biol. 1988;4:93-126.
	C35	Saksela, Plasminogen activation and regulation of pericellular proteolysis. Biochim Biophys Acta. 1985 Nov 12;823(1):35-65.
	C36	Seetharam et al., Purification and characterization of active and latent forms of recombinant plasminogen activator inhibitor I produced in Escherichia coli. Biochemistry. 1992 Oct 20;31(41):9877-82.
	C37	Swiercz et al., Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator. Oncol Rep. 1999 May-Jun;6(3):523-6.
	C38	van Mourik et al., Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem. 1984 Dec 10;259(23):14914-21.
	C39	Vaughan et al., Studies of recombinant plasminogen activator inhibitor-I in rabbits. Pharmacokinetics and evidence for reactivation of latent plasminogen activator inhibitor-I in vivo. Circ Res. 1990 Nov;67(5):1281-6.
	C40	Wilson et al., Plasminogen activator and metalloprotease activities of Du-145, PC-3, and L-LN-PC-3-1A human prostate tumors grown in nude mice: correlation with tumor invasive behavior. Cell Mol Biol Res. 1993;39(8):751-60.
	C41	Wiman et al., Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor. J Biol Chem. 1984 Mar 25;259(6):3644-7.
	C42	Wiman et al., Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clin Chim Acta. 1983 Jan 24;127(2):279-88.
	C43	Wiman et al., The role of the fibrinolytic system in deep vein thrombosis. J Lab Clin Med. 1985 Feb;105(2):265-70.
	C44	Wun et al., Affinity purification of active plasminogen activator inhibitor-I (PAI-1) using immobilized anhydrourokinase. Demonstration of the binding, stabilization, and activation of PAI-1 by vitronectin. J Biol Chem. 1989 May 15;264(14):7862-8.

EXAMINER	<i>Chase Rohr</i>	DATE CONSIDERED	<i>12/23/05</i>
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			